Magnifying glass in front of a stack of files of papers
PLOS ONE Pulls Five Papers Tied to Alzheimer’s Drug Controversy
The retracted studies were coauthored by a scientist who worked on an Alzheimer’s therapy in development by Cassava Sciences, a company reportedly under investigation for providing falsified data to the FDA.
PLOS ONE Pulls Five Papers Tied to Alzheimer’s Drug Controversy
PLOS ONE Pulls Five Papers Tied to Alzheimer’s Drug Controversy

The retracted studies were coauthored by a scientist who worked on an Alzheimer’s therapy in development by Cassava Sciences, a company reportedly under investigation for providing falsified data to the FDA.

The retracted studies were coauthored by a scientist who worked on an Alzheimer’s therapy in development by Cassava Sciences, a company reportedly under investigation for providing falsified data to the FDA.

ABOVE: © ISTOCK.COM, BERNIE_PHOTO
Securities and Exchange Commission
SEC Charges uBiome Founders with Defrauding Investors
Catherine Offord | Mar 23, 2021
The microbiome-testing company made misleading claims about its prospects and about its business strategy, which allegedly relied on fooling doctors into ordering unnecessary tests, according to the US government.
DNA strands on a blue background
“Co-op” Lets Users Barter DNA and Health Information for Shares
Shawna Williams | Dec 7, 2018
LunaDNA receives Securities and Exchange Commission approval to treat the data as currency.
Theranos Goes Under
Sukanya Charuchandra | Sep 5, 2018
The discredited blood-testing company announced its decision to close in a company-wide email.
SEC Charges Theranos With Fraud
Jim Daley | Mar 14, 2018
The company raised more than $700 million based on false claims to investors, according to the complaint.